Nitz UA, Gluz O, Christgen M, Grischke EM, et al. Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertu Ann Oncol 2022 Jan 7. pii: S0923-7534(21)04883.
PMID: 35012798